Scarica l'app Stockscreener
0.7246
2.08%
-0.0154
Dare Bioscience Inc Borsa (DARE) Ultime notizie
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting - The Manila Times
Daré Bioscience Announces Phase 1 Sildenafil Cream Data to Be Presented at SMSNA Annual Fall Scientific Meeting - Quiver Quantitative
Daré Bioscience Faces Nasdaq Minimum Bid Price Noncompliance - TipRanks
Daré Bioscience Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection - manilatimes.net
Warrants covering about 45% of existing shares await a vote at Daré Bioscience (NASDAQ: DARE). - Stock Titan
Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil - manilatimes.net
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com Australia
Dare Bioscience amends bylaws to lower quorum for shareholder meetings By Investing.com - Investing.com Australia
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com Nigeria
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com South Africa
Dare Bioscience amends bylaws to lower quorum for shareholder meetings By Investing.com - Investing.com Canada
Dare Bioscience amends bylaws to lower quorum for shareholder meetings - Investing.com
Form 8K Dare Bioscience Inc For: 11 September By Investing.com - Investing.com India
Daré Bioscience at H.C. Wainwright conference: turning to sales By Investing.com - Investing.com Canada
Daré Bioscience at H.C. Wainwright conference: turning to sales By Investing.com - Investing.com Nigeria
Daré Bioscience at H.C. Wainwright conference: turning to sales - Investing.com
Daré Bioscience at H.C. Wainwright conference: turning to sales By Investing.com - Investing.com India
Daré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand - The Manila Times
Daré Bioscience Presentation for H.C. Wainwright 28th - GlobeNewswire
Dare Bioscience amends bylaws to lower quorum for shareholder meetings By Investing.com - Investing.com South Africa
Dare Bioscience amends bylaws to lower quorum for shareholder meetings - Investing.com
Dare Bioscience (NASDAQ: DARE) Eyes Up to $12.4M from Warrants to Boost 503B and Consumer Health Initiatives - kalkinemedia.com
Patient data from an Alzheimer’s drug is anticipated by late 2027 or early 2028 - Stock Titan
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Dare Bioscience (DARE) Secures $908K NIH Grant Amidst Challengin - GuruFocus
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com India
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com Nigeria
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com UK
Daré Bioscience Announces New NIH Funding Award for - GlobeNewswire
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth - manilatimes.net
Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold - Stock Titan
Dare Bioscience Inc (DARE) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Dare Bioscience Inc (DARE) Key Financial Ratios – Valuation, Profitability & More - Value Research
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Barchart.com
IPO Databook: Daré Bioscience (DARE US)Aug 2026 - Smartkarma
Daré Bioscience publishes sildenafil cream study results - Investing.com
Daré Bioscience publishes sildenafil cream study results By Investing.com - Investing.com India
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Barchart.com
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Yahoo Finance
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - manilatimes.net
Daré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment - Yahoo Finance
Daré Bioscience Highlights Commercial Transition, Ovaprene Phase 3 Progress and Near-Term Growth Catalysts - Quiver Quantitative
L1 Capital caps Dare Bioscience (DARE) stake at 9.99% - Stock Titan
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - The Globe and Mail
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):